Okairos: Okay After All

On May 29th, 2013, GlaxoSmithKline (GSK) announced the acquisition of Okairos in an all-cash deal worth $325 million US. The Okairos acquisition helps complement the pharma giant’s existing vaccine technology and expertise and will enable GSK to continue its work developing the next generation of vaccines.

Read more »